The stock of PRA Health Sciences Inc (NASDAQ:PRAH) reached all time high today, Sep, 30 and still has $70.30 target or 24.00% above today’s $56.69 share price. This indicates more upside for the $3.41 billion company. This technical setup was reported by Barchart.com. If the $70.30 PT is reached, the company will be worth $818.40 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 184,976 shares traded hands. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 25.70% since February 26, 2016 and is uptrending. It has outperformed by 15.27% the S&P500.
Analysts await PRA Health Sciences Inc (NASDAQ:PRAH) to report earnings on November, 7. They expect $0.62 earnings per share, up 24.00% or $0.12 from last year’s $0.5 per share. PRAH’s profit will be $37.29M for 22.86 P/E if the $0.62 EPS becomes a reality. After $0.61 actual earnings per share reported by PRA Health Sciences Inc for the previous quarter, Wall Street now forecasts 1.64% EPS growth.
PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage
Out of 9 analysts covering PRA Health Sciences (NASDAQ:PRAH), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. PRA Health Sciences has been the topic of 13 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Citigroup maintained PRA Health Sciences Inc (NASDAQ:PRAH) on Thursday, September 22 with “Buy” rating. The rating was upgraded by KeyBanc Capital Markets to “Overweight” on Monday, June 13. The company was downgraded on Tuesday, September 6 by UBS. The rating was upgraded by SunTrust to “Buy” on Monday, March 28. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Equal-Weight” rating given on Tuesday, June 21 by First Analysis. The rating was reinitiated by Credit Suisse on Friday, August 14 with “Outperform”. The company was initiated on Tuesday, June 21 by Credit Suisse. The firm earned “Neutral” rating on Thursday, November 19 by Suntrust Robinson. As per Thursday, November 19, the company rating was initiated by SunTrust. Citigroup upgraded it to “Buy” rating and $53 target price in Wednesday, May 4 report.
According to Zacks Investment Research, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.”
More important recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Businesswire.com which released: “Takeda and PRA Health Sciences Announce Transformational Clinical Development …” on September 12, 2016, also Globenewswire.com published article titled: “PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2015 Results …”, Nasdaq.com published: “PRA Health Sciences, Inc. Reports Second Quarter 2016 Results” on July 28, 2016. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) was released by: Globenewswire.com and their article: “PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 …” with publication date: April 27, 2016.
PRAH Company Profile
PRA Health Sciences, Inc., incorporated on June 21 2013, is a contract research organization (CRO). The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Firm provides its clients with clinical development service offerings, which includes both traditional, project Phase I through Phase IV services, as well as embedded and functional outsourcing services. The Company’s clinical development platform includes over 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.